Detailed price information for Skye Bioscience Inc (SKYE-Q) from The Globe and Mail including charting and trades.

Detailed price information for Skye Bioscience Inc (SKYE-Q) from The Globe and Mail including charting and trades.

As previously reported, Evercore ISI initiated coverage of Skye Bioscience (SKYE) with an Outperform rating and $10 price target Nimacimab is the ...

Skye Bioscience Inc (SKYE) reports significant advancements in clinical trials and financial stability, despite increased ...

Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025Patient enrollment in ...

Evercore ISI analyst Michael DiFiore initiated coverage of Skye Bioscience (SKYE) with an Outperform rating and $10 price target Published first ...

Skye Bioscience nears Phase IIa data for nimacimab, targeting obesity treatment gaps with robust preclinical insights.

Get the latest Skye Bioscience Inc. R (09R.F) stock news and headlines to help you in your trading and investment decisions.

SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and ...

SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other ...

SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other ...